Cullinan Therapeutics, Inc.
CGEM
$20.34
$0.703.56%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -10.46% | -5.30% | 0.43% | 12.76% | 17.77% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -5.49% | 15.04% | 22.71% | 28.87% | 28.04% |
| Operating Income | 5.49% | -15.04% | -22.71% | -28.87% | -28.04% |
| Income Before Tax | 0.95% | -23.75% | -31.30% | -35.76% | -30.59% |
| Income Tax Expenses | -- | -- | -- | 100.83% | 100.83% |
| Earnings from Continuing Operations | 1.00% | -23.67% | -31.21% | -49.02% | -43.47% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -100.00% | -100.00% |
| Net Income | 1.00% | -23.67% | -31.36% | -51.05% | -45.44% |
| EBIT | 5.49% | -15.04% | -22.71% | -28.87% | -28.04% |
| EBITDA | 5.50% | -15.06% | -22.75% | -28.91% | -28.09% |
| EPS Basic | 1.35% | -17.29% | -12.41% | -20.95% | -7.10% |
| Normalized Basic EPS | 3.10% | -20.31% | -18.93% | -15.63% | -3.67% |
| EPS Diluted | 1.35% | -17.29% | -12.41% | -20.95% | -7.10% |
| Normalized Diluted EPS | 3.10% | -20.31% | -18.93% | -15.63% | -3.67% |
| Average Basic Shares Outstanding | 2.30% | 2.98% | 9.87% | 18.26% | 27.91% |
| Average Diluted Shares Outstanding | 2.30% | 2.98% | 9.87% | 18.26% | 27.91% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |